In­novent Bi­o­log­ics high­lights sub­group of lung can­cer pa­tients in ear­ly-stage study of bis­pe­cif­ic

In­novent Bi­o­log­ics re­port­ed Mon­day that 20.8% of ad­vanced lung can­cer pa­tients saw their tu­mors shrink at least 30% af­ter re­ceiv­ing an ex­per­i­men­tal bis­pe­cif­ic an­ti­body that’ …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER